Quantitative PCR and HER2 testing in breast cancer: A technical and cost-effectiveness analysis

American Journal of Clinical Pathology

Volumn 129, Issue 4, 2008, Pages 563-570

  Barberis, Massimo ^a   Pellegrini, Caterina ^b,c   Cannone, Maria ^a   Arizzi, Carmelo ^a   Coggi, Guido ^b,c   Bosari, Silvano ^b,c,d  

^a IRCCS   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d SAN PAOLO HOSPITAL   (Italy)

Author keywords

Breast cancer; FISH; Fluorescent in situ hybridization; HER2; Immunohistochemistry; Quantitative real time RT PCR; Reverse transcription polymerase chain reaction; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; RNA;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; APOCRINE GLAND; BREAST TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GENE EXPRESSION; GENETICS; LUNG CARCINOMA; METABOLISM; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; PAPILLARY CARCINOMA; PATHOLOGY; SWEAT GLAND TUMOR;

ADULT; AGED; AGED, 80 AND OVER; APOCRINE GLANDS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, PAPILLARY; COST-BENEFIT ANALYSIS; FEMALE; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SWEAT GLAND NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 42949093222     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/1AKQDQ057PQT9AKX     Document Type: Article

References (37)

1. Hillner BE, Smith TJ. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol. 2007;25:611-613.
2. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-1878.
3. Vogel CL, Franco SX. Clinical experience with trastuzumab (Herceptin). Breast J. 2003;9:452-462.
4. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19:2714-2721.
5. Onody P, Bertrand F, Muzeau F, et al. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/ neu status determination: application to node-negative breast cancer. Arch Pathol Lab Med. 2001;125:746-750.
6. de Cremoux P, Martin EC, Vincent-Salomon A, et al. Quantitative PCR analysis of c-erbB-2 (HER-2/neu) gene amplification and comparison with p185 (HER-2/neu) protein expression in breast cancer drill biopsies. Int J Cancer. 1999;83:157-161.
7. Bieche I, Onody P, Laurendeau I, et al. Real-time reverse transcription PCR assay for future management of ERBB2-based clinical applications. Clin Chem. 1999;45:1148-1156.
8. Mrhalova M, Kodet R, Kalinova M, et al. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB2 protein expression and ERBB2 gene copy number. Pathol Res Pract. 2003;199:453-461.
9. Potemski P, Pluciennik E, Bednarek AK, et al. A comparative assessment of HER2 status in operable breast cancer by realtime RT-PCR and by immunohistochemistry. Med Sci Monit. 2006;12:MT57-MT61.
10. Vinatzer U, Dampier B, Streubel B, et al. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res. 2005;11:8348-8357.
11. Bossard C, Bieche I, Le Doussal V, et al. Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma. Anticancer Res. 2005;25:4679-4683.
12. Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2004;164:35-42.
13. Gjerdrum LM, Sorensen BS, Kjeldsen E, at al. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma. J Mol Diagn. 2004;6:42-51.
14. Sapino A, Marchio C, Senetta R, et al. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch. 2006;449:288-296.
15. Kraus MH, Popescu NC, Amsbaugh SC, et al. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanism. EMBO J. 1987;6:605-610.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
17. Birner P, Oberhuber G, Stani J, et al. Evaluation of the United States Food and Drug Administration - approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res. 2001;7:1669-1675.
18. Bijwaard KE, Aguilera NS, Monczak Y, et al. Quantitative realtime reverse transcription PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem. 2001;47:195-201.
19. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:research0034.1-0034.11. doi: 10.1186/gb-2002-3-7-research0034.
20. Pellegrini C, Falleni M, Marchetti A, et al. Her-2/neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization and immunohistochemistry. Clin Cancer Res. 2003;9:3645-3652.
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
22. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med. 2005;353:1673-1684.
23. O'Shaughnessy J. Molecular signatures predict outcomes of breast cancer. N Engl J Med. 2006;355:615-617.
24. Masood S. Raising the bar: a plea for standardization and quality improvement in the practice of breast pathology [editorial]. Breast J. 2006;12:409-412.
25. Bartlett JM, Ibrahim M, Jasani B, et al. External quality assurance of HER2 fluorescence in situ hybridization testing: results of a UK NEQAS pilot scheme. J Clin Pathol. 2007;60:816-819.
26. Zhang D, Salto-Tellez M, Putti TC, et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol. 2003;16:79-84.
27. Bhargava R, Lal P, Chen B. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma. Diagn Mol Pathol. 2004;13:213-216.
28. Rimm DL, Camp RL, Charette LA, et al. Amplification of tissue by construction of tissue microarrays. Exp Mol Pathol. 2001;70:255-264.
29. Stanta G, Mucelli SP, Petrera F, et al. A novel fixative improves opportunities of nucleic acids and proteomic analysis in human archive's tissue. Diagn Mol Pathol. 2006;15:115-123.
30. Stanta G, Bonin S. RNA quantitative analysis from fixed and paraffin-embedded tissues: membrane hybridization and capillary electrophoresis. Biotechniques. 1998;24:271-276.
31. Specht K, Richter T, Muller U, et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol. 2001;158:419-429.
32. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression - based predictors for breast cancer. N Engl J Med. 2006;355:560-569.
33. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23:7265-7277.
34. Tse C, Brault D, Gligorov J, et al. Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem. 2005;51:1093-1101.
35. Bose S, Mohammed M, Shintaku P, et al. HER-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/HER-2/neu polysomy. Breast J. 2001;7:337-344.
36. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 2003;77:109-114.
37. Wang S, Hossein Saboorian M, Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol. 2002;15:137-145.